|
Mylan Sues FDA Over Exclusivity for Four Diovan Generics
Mylan is suing the FDA over its refusal to grant 180-day exclusivity for the company’s four generic versions of Novartis’ high blood pressure drug Diovan.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives